Company Overview and News
South Korea has signed defence agreements with Brunei and Cambodia as Seoul looks to further expand its defence export profile across Southeast Asia.
South Korea's Ministry of National Defense (MND) has proposed a 2019 defence budget of KRW46.7 trillion (USD42 billion) to support its new military reform programme.
South Korea’s Ministry of National Defense (MND) announced on 22 August reforms to introduce greater levels of transparency in military procurement.
North Korea’s nuclear weapons programme and potential thaw in relations with the US, a border stand-off between India and China, fighting in the southern Philippines, large naval procurement programmes in Southeast Asia, and a new US strategy for Afghanistan have made for a busy year in the Asia- Pacific region.
Taiwan has welcomed a potential shift in policy by the United States government to facilitate military sales to the country on a case-by-case basis as opposed to the current approach of ‘bundling’ several defence deals together.
China’s People’s Liberation Army Air Force (PLAAF) has conducted its first airdrop and air delivery training exercise using the Xian Aircraft Corporation Y-20 Kunpeng strategic transport aircraft, the Ministry of National Defense (MND) in Beijing announced on 8 May.
South Korea and the Philippines have agreed to expand military industrial collaboration in support of existing and future defence trade programmes.
China’s People’s Liberation Army Navy (PLAN) paraded 48 naval vessels, 76 aircraft, and 10,000 personnel in a fleet review before President Xi Jinping in the South China Sea on 12 April.
Taiwan’s Ministry of National Defense (MND) has said the US government has awarded a marketing licence in support of its efforts to develop and construct diesel-electric submarines.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:MND / MND on message board site Silicon Investor.